{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:10:38Z","timestamp":1778112638784,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"DOI":"10.7759\/cureus.108385","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:13:52Z","timestamp":1778109232000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity"],"prefix":"10.7759","author":[{"given":"Masuho","family":"Saburi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takata","family":"Hiroyuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takami","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers CL","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999, 340:1330-40. 10.1056\/NEJM199904293401706","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-721662","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"128","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 128:462-3. 10.1182\/blood-2016-06-721662","journal-title":"Blood"},{"key":"ref3","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating chronic-phase CML","volume":"94","author":"Silver RT","year":"1999","unstructured":"Silver RT, Woolf SH, Hehlmann R, et al.. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating chronic-phase CML. Blood. 1999, 94:1517-36.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien SG","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, et al.. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348:994-1004. 10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio G","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al.. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010, 362:2251-9. 10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian H","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al.. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010, 362:2260-70. 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, et al.. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018, 36:231-7. 10.1200\/JCO.2017.74.7162","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with CML who have maintained complete molecular remission (STIM trial)","volume":"11","author":"Mahon FX","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, et al.. Discontinuation of imatinib in patients with CML who have maintained complete molecular remission (STIM trial). Lancet Oncol. 2010, 11:1029-35. 10.1016\/S1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf TH","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, et al.. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022, 36:1825-33. 10.1038\/s41375-022-01589-y","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02878-x","article-title":"Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"112","author":"Hino M","year":"2020","unstructured":"Hino M, Matsumura I, Fujisawa S, et al.. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. Int J Hematol. 2020, 112:24-32. 10.1007\/s12185-020-02878-x","journal-title":"Int J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03435-4","article-title":"Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study","volume":"116","author":"Ono T","year":"2022","unstructured":"Ono T, Hino M, Matsumura I, et al.. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study. Int J Hematol. 2022, 116:871-82. 10.1007\/s12185-022-03435-4","journal-title":"Int J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann M","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, et al.. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016, 30:48-56. 10.1038\/leu.2015.261","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford S","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, et al.. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008, 112:3330-8. 10.1182\/blood-2008-04-150680","journal-title":"Blood"},{"key":"ref14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). (2017). Accessed. November 27, 2025: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8x11.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al.. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020, 34:966-84. 10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0101-1","article-title":"Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia","volume":"7","author":"Mita A","year":"2018","unstructured":"Mita A, Abumiya M, Miura M, et al.. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018, 7:9. 10.1186\/s40164-018-0101-1","journal-title":"Exp Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018, 11:143. 10.1186\/s13045-018-0685-2","journal-title":"J Hematol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.03.033","article-title":"Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era","volume":"34","author":"Kim DW","year":"2010","unstructured":"Kim DW, Banavali SD, Bunworasate U, et al.. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 2010, 34:1459-71. 10.1016\/j.leukres.2010.03.033","journal-title":"Leuk Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491076-treatment-discontinuation-of-first-line-bosutinib-in-a-real-world-cohort-of-patients-with-chronic-myeloid-leukemia-impact-of-hepatic-toxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:13:53Z","timestamp":1778109233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491076-treatment-discontinuation-of-first-line-bosutinib-in-a-real-world-cohort-of-patients-with-chronic-myeloid-leukemia-impact-of-hepatic-toxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.108385","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}